Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 541 | 21% |
| 2020 | 3 | 467 | 25% |
| 2021 | 3 | 518 |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.7 | 30% | 6,960 in 2030+2.2%/yr |
| Pennsylvania | 52 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 22 | 921−1.3%/yr | −1.3%/yr | 4.10.7× | 2% | 1,150 in 2030+3.8%/yr |
| BPH procedures |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
| ≈ 630 |
| – |
| 2026 est. | ≈ 720 | – |
| 29% |
| 2022 | 5 | 542 | 33% |
| 2023 | 4 | 540 | 37% |
| 2024 | 3 | 531 | 39% |
| 2025 from claims | – | 632 511–742 | 40% |
| 2026 forecast | – | 725 568–910 | 35% |
| 2027 forecast | – | 766 568–1,013 | 34% |
| 2028 forecast | – | 810 573–1,118 | 34% |
| 2029 forecast | – | 856 582–1,228 | 33% |
| 2030 forecast | – | 905 593–1,343 | 33% |
In 2025, 94% hospital outpatient, 6% surgery center. The share outside the hospital has moved −3 pts since 2019.
| 4,366−2%/yr |
| −2%/yr |
| 3.5 |
| 10% |
| 4,620 in 2030+0.9%/yr |
| Massachusetts | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.6 | 17% | 3,720 in 2030+2.6%/yr |
| New Jersey | 25 | 2,622+0.6%/yr | +0.6%/yr | 2.7 | 20% | 3,090 in 2030+2.8%/yr |
| Connecticut | 9 | 999−0.1%/yr | −0.1%/yr | 3.3 | 8% | 1,420 in 2030+6%/yr |
| Rhode Island | 6 | 346−0.6%/yr | −0.6%/yr | 4.2 | 0% | 430 in 2030+3.6%/yr |
| Maine | 3 | 290−6%/yr | −6%/yr | 2.0 | 7% | 370 in 2030+4%/yr |
| Vermont | 4 | 193−5.7%/yr | −5.7%/yr | 1.8 | 9% | 360 in 2030+11%/yr |
| 11 |
| 730−2.7%/yr |
| −2.7%/yr |
| 3.20.7× |
| 25% |
| 880 in 2030+3.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 5 | 344−2.3%/yr | −2.3%/yr | 1.50.8× | 0% | 460 in 2030+4.9%/yr |
| Prostatectomy & nephrectomy | 5 | 194−3.3%/yr | −3.3%/yr | 0.90.8× | 0% | 300 in 2030+7.6%/yr |
No metro breakdown yet.
Hologic Sales And Service leads with 96% of company spending on these surgeons in 2025, +50 pts on 2024.
In 2025, 2 companies reported engagement with New Hampshire’s surgeons worth $455 in consulting, speaking, meals and travel tied to these products, about $152 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.